Maxion's Innovations Sang Backed by $72M Boost
Deal News | Mar 17, 2025 | General Catalyst Partners LLC
General Catalyst Partners LLC has led a Series A funding round, raising $72 million for Maxion Therapeutics, underscoring their mission to revolutionize patient care by investing in the life sciences. This investment highlights Maxion's innovative approaches to therapeutics, especially focusing on traditionally challenging targets like ion channels and G protein-coupled receptors (GPCRs) using its proprietary KnotBody platform. This platform leverages advanced protein engineering and computational techniques to create biologics with the potential to address diseases such as autoimmune diseases, cardiovascular disease, and chronic pain, where traditional methods have fallen short. The funds from this round will progress Maxion's lead program, MAX-001, advance the KnotBody platform, and broaden their therapeutic pipeline.
Sectors
- Biotechnology and Pharmaceuticals
Geography
- United States – General Catalyst Partners LLC is based in the United States and has made the investment in Maxion Therapeutics, drawing part of the geographical focus to the region.
- United Kingdom – Maxion Therapeutics operates out of Cambridge in the United Kingdom, making this location significant in the context of the investment and its biotechnological advancements.
Industry
- Biotechnology and Pharmaceuticals – The article focuses on Maxion Therapeutics' development of novel biologics, indicating its place within the biotechnology and pharmaceutical industries, emphasizing innovation in drug development.
Financials
- $72M – The amount raised in the Series A funding round led by General Catalyst Partners for Maxion Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| General Catalyst Partners LLC | Lead Investor in Series A | Company | A leading private equity firm investing in life sciences as part of a broad-based venture capital strategy. |
| Maxion Therapeutics | Investment Recipient | Company | A biotechnology company focused on developing biologics for effective treatment of diseases involving traditionally unreachable targets. |
| Dr. Arndt Schottelius | CEO | People | A seasoned drug developer leading Maxion Therapeutics, bringing expertise in biologics development. |
| Dr. John McCafferty | CTO and Co-founder | People | Co-inventor of the KnotBody technologies and notable for contributions to antibody-phage display. |
| Dr. Aneesh Karatt-Vellatt | CSO and Co-founder | People | Antibody discovery expert and technical leader of Maxion's KnotBody platform. |